Tonix Pharmaceuticals Holding Corp. announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA. Published in Clinical Pharmacology in Drug Development, the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA's proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism.
The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to the long-acting metabolite norcyclobenzaprine, supporting durable analgesic benefits with improved tolerability. This development is significant because TONMYA represents the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years, offering a non-opioid alternative for a chronic pain condition affecting millions of adults.
The pharmacokinetic research published in Clinical Pharmacology in Drug Development demonstrates how the sublingual delivery system fundamentally changes how the medication interacts with the body. By bypassing first-pass hepatic metabolism through transmucosal absorption, TONMYA achieves more rapid onset while potentially reducing side effects associated with traditional oral formulations. This mechanism is particularly important for fibromyalgia patients who often experience disrupted sleep patterns and require medications that work effectively during nighttime hours.
Tonix Pharmaceuticals markets FDA-approved TONMYA as a first-in-class, non-opioid analgesic medicine for fibromyalgia treatment. The company also markets two treatments for acute migraine in adults: Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray). Tonix's development portfolio includes additional CNS disorder treatments, with TNX-102 SL being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense.
The implications of this research extend beyond fibromyalgia treatment, as the pharmacokinetic principles demonstrated with TONMYA could influence future drug development for other conditions requiring rapid onset with reduced side effects. The study's publication in a peer-reviewed journal adds scientific credibility to the company's claims about TONMYA's mechanism of action and potential benefits. For investors and industry observers, the latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
For the broader pharmaceutical industry, TONMYA's approval and the supporting pharmacokinetic research represent progress in developing non-opioid pain management solutions at a time when opioid addiction remains a significant public health concern. The medication's unique delivery system and mechanism of action could serve as a model for future pain management drugs seeking to balance efficacy with safety. The full press release detailing these developments can be viewed at https://ibn.fm/8zoXF.
